These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 19653056)
21. Bosentan for patients with chronic thromboembolic pulmonary hypertension. Vassallo FG; Kodric M; Scarduelli C; Harari S; Potena A; Scarda A; Piattella M; Cassandro R; Confalonieri M Eur J Intern Med; 2009 Jan; 20(1):24-9. PubMed ID: 19237088 [TBL] [Abstract][Full Text] [Related]
22. Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children. Gilbert N; Luther YC; Miera O; Nagdyman N; Ewert P; Berger F; Lange PE; Schulze-Neick I Z Kardiol; 2005 Sep; 94(9):570-4. PubMed ID: 16142516 [TBL] [Abstract][Full Text] [Related]
23. The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Hasegawa EM; Caleiro MT; Fuller R; Carvalho JF Lupus; 2009 Jun; 18(7):618-21. PubMed ID: 19433462 [TBL] [Abstract][Full Text] [Related]
25. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan. Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502 [TBL] [Abstract][Full Text] [Related]
26. Review of bosentan in the management of pulmonary arterial hypertension. Gabbay E; Fraser J; McNeil K Vasc Health Risk Manag; 2007; 3(6):887-900. PubMed ID: 18200808 [TBL] [Abstract][Full Text] [Related]
27. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis. Chen X; Zhai Z; Huang K; Xie W; Wan J; Wang C Clin Respir J; 2018 Jun; 12(6):2065-2074. PubMed ID: 29393580 [TBL] [Abstract][Full Text] [Related]
28. Successful bosentan therapy in a case of pulmonary arterial hypertention developed during immunosuppressive therapy for lupus nephritis. Ueda Y; Takahashi Y; Yamashita H; Kaneko H; Mimori A Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(2):99-104. PubMed ID: 21628852 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. Benza RL; Rayburn BK; Tallaj JA; Coffey CS; Pinderski LJ; Pamoukian SV; Bourge RC Chest; 2006 Apr; 129(4):1009-15. PubMed ID: 16608951 [TBL] [Abstract][Full Text] [Related]
30. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension. Mok MY; Tsang PL; Lam YM; Lo Y; Wong WS; Lau CS Lupus; 2007; 16(4):279-85. PubMed ID: 17439935 [TBL] [Abstract][Full Text] [Related]
31. Bosentan. Prakash A; Perry CM Am J Cardiovasc Drugs; 2002; 2(5):335-43; discussion 343. PubMed ID: 14727963 [TBL] [Abstract][Full Text] [Related]
32. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Valerio CJ; Handler CE; Kabunga P; Smith CJ; Denton CP; Coghlan JG Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of bosentan treatment for portopulmonary hypertension associated with syncope. Sato A; Maie K; Ohno Y; Yoshida T; Ito E; Tanabe Y; Aizawa Y Int Heart J; 2011; 52(4):243-5. PubMed ID: 21828952 [TBL] [Abstract][Full Text] [Related]
34. Effects of long-term bosentan in children with pulmonary arterial hypertension. Rosenzweig EB; Ivy DD; Widlitz A; Doran A; Claussen LR; Yung D; Abman SH; Morganti A; Nguyen N; Barst RJ J Am Coll Cardiol; 2005 Aug; 46(4):697-704. PubMed ID: 16098438 [TBL] [Abstract][Full Text] [Related]
36. [Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis]. Volkov AV; Kurmukov IA; Yudkina NN; Glukhova SI; Nikolaeva EV Ter Arkh; 2015; 87(1):49-56. PubMed ID: 25823269 [TBL] [Abstract][Full Text] [Related]
37. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan]. Martynyuk TV; Aleevskaya AM Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938 [TBL] [Abstract][Full Text] [Related]
38. Ortner's syndrome caused by pulmonary arterial hypertension associated with mixed connective tissue disease. Ogawa-Momohara M; Muro Y; Hirashiki A; Fujimoto Y; Kondo T; Akiyama M Clin Exp Rheumatol; 2016; 34(6):1125. PubMed ID: 27463267 [No Abstract] [Full Text] [Related]
39. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. Oldfield V; Lyseng-Williamson KA Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392 [TBL] [Abstract][Full Text] [Related]
40. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Sitbon O; Gressin V; Speich R; Macdonald PS; Opravil M; Cooper DA; Fourme T; Humbert M; Delfraissy JF; Simonneau G Am J Respir Crit Care Med; 2004 Dec; 170(11):1212-7. PubMed ID: 15317666 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]